Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scotland's HTA Body Says Fast-Track Yes To UCB’s Bimzelx

Janssen's Ponvory To Be Funded For Relapsing-Remitting MS

Executive Summary

The Scottish health technology appraisal body also OKd Janssen's Ponvory and new indications for AstraZeneca’s Tagrisso, Roche’s Tecentriq and MSD’s Keytruda. It also said it could not make recommendations on a number of drugs because manufacturers had not made a submission to the SMC.

You may also be interested in...



New Sickle Cell Treatment & Ten Other Drugs Win English Funding Approval

Health technology assessment body NICE has also issued guidances rejecting three products.

Scottish Funding No For Two Orphans As SMC Tries To Catch Up After COVID-19 Backlog

Two orphan drugs, Chiesi’s Proscybi and Insmed’s Arikayce, were rejected for funding on the Scottish National Health Service.

UCB’s Bimekizumab Gets Fast-Track Funding For Severe Psoriasis In England

It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.

Related Content

Topics

UsernamePublicRestriction

Register

PS145239

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel